A Form 4 filed with the SEC on September 3, 2026, reports that Lars Holtug, a director of Ascendis Pharma A/S (NASDAQ:ASND), sold 236 ordinary shares on September 2, 2026.
William P. Stiritz, Chairman Emeritus of Post Holdings, Inc., filed a Form 4 on September 3, 2026, disclosing the sale of 384,132 shares of common stock indirectly held by his spouse across two trading days, September 1 and September 2, 2026.
Director Frances Arnold filed a Form 4 with the SEC on September 3, 2026, disclosing the sale of 1,000 shares of Generate Biomedicines, Inc. common stock on September 1, 2026, under a pre-established Rule 10b5-1 trading plan.
Ravi Inukonda, Chief Financial Officer of DoorDash, Inc. (NASDAQ:DASH), filed a Form 4 on September 3, 2026, disclosing the exercise of a stock option and the sale of Class A Common Stock on September 1, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.
DoorDash, Inc. (NASDAQ:DASH) Chief Executive Officer Tony Xu filed a Form 4 on September 3, 2026, disclosing transactions in Class A Common Stock dated September 1, 2026, including a stock option exercise and a same-day sale under a pre-established Rule 10b5-1 trading plan.
Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc. (NASDAQ:MRNA), reported multiple transactions in Moderna common stock and derivative securities on September 1, 2026, in a Form 4 filed with the SEC on September 3, 2026.
A Form 4 filed on September 3, 2026 with the SEC reports that Andy Fang, a director of DoorDash, Inc. (NASDAQ:DASH), disposed of 15,000 shares of Class A Common Stock on September 1, 2026 under a pre-established Rule 10b5-1 trading plan.
Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge filed a Form 4 on September 3, 2026, disclosing the vesting of restricted stock units and a related tax-withholding share disposition dated September 1, 2026.
A Form 4 filed on September 3, 2026, with the U.S. Securities and Exchange Commission discloses two transactions in Moderna, Inc. common stock by Chief Financial Officer James M. Mock on September 1, 2026.
A Form 4 filed on September 3, 2026 disclosed that Muna Bhanji, a director of Veracyte, Inc. (NASDAQ:VCYT), sold 1,864 shares of common stock on September 1, 2026 pursuant to a pre-established Rule 10b5-1 trading plan.